Weight management
Compounded medication, when prescribed, is not FDA approved. Tirzepatide is a prescription medicine that acts on GIP and GLP-1 receptors involved in appetite and food intake. Our weight-management pathway starts with a clinician’s review of your goals, medical history, medicines and individual risks. The clinician decides whether tirzepatide is appropriate and, if prescribing, selects the preparation and treatment plan. Ongoing use and changes require clinical direction; choosing this pathway does not buy a prescription or a promised amount of weight loss.
Tirzepatide can cause gastrointestinal effects, including nausea, vomiting, diarrhea and constipation, and has important warnings and contraindications. Tell the clinician about pregnancy or pregnancy plans, other medicines, and any personal or family history of medullary thyroid carcinoma or MEN 2. Read the full information for the medicine actually prescribed. Compounded medicines are not FDA approved. FDA does not assess their safety, effectiveness or quality before marketing. They are not FDA-approved generics or interchangeable substitutes for approved medicines. A clinician must determine whether a compounded preparation is appropriate; the pharmacy is responsible for its preparation and labeling.
Eligibility requires a licensed clinician’s evaluation. A prescription and results are not guaranteed.
Evaluation link disconnected for website review.
Weight management
Compounded medication, when prescribed, is not FDA approved. Semaglutide is a prescription medicine that acts on GLP-1 receptors involved in appetite and food intake. A licensed clinician reviews whether it fits your health history, current medicines and weight-management goals, and determines any preparation, prescription and follow-up plan. Medical review can also result in a different recommendation, further evaluation or no prescription. Do not start, combine or change medication on the basis of a product page.
Semaglutide can cause gastrointestinal effects, including nausea, vomiting, diarrhea and constipation, and has important warnings and contraindications. Tell the clinician about pregnancy or pregnancy plans, other medicines, and any personal or family history of medullary thyroid carcinoma or MEN 2. Read the full information for the medicine actually prescribed. Compounded medicines are not FDA approved. FDA does not assess their safety, effectiveness or quality before marketing. They are not FDA-approved generics or interchangeable substitutes for approved medicines. A clinician must determine whether a compounded preparation is appropriate; the pharmacy is responsible for its preparation and labeling.
Eligibility requires a licensed clinician’s evaluation. A prescription and results are not guaranteed.
Evaluation link disconnected for website review.
Weight management
Architek’s published microdosing model uses compounded medicines and clinician-controlled low doses. This tirzepatide evaluation pathway requires a clinician to assess whether treatment is appropriate and select any patient-specific preparation and dose. Tirzepatide acts on GIP and GLP-1 receptors involved in appetite and food intake. “Microdose” is not a standardized FDA-approved regimen or a promise of fewer side effects. Do not infer a dose or schedule from this name or change treatment without clinical direction.
The risks and contraindications of tirzepatide still matter when a smaller dose is considered; a smaller dose is not a safety guarantee. Discuss pregnancy, other medicines, and personal or family history of medullary thyroid carcinoma or MEN 2 with the clinician. Compounded medicines are not FDA approved. FDA does not assess their safety, effectiveness or quality before marketing. They are not FDA-approved generics or interchangeable substitutes for approved medicines. A clinician must determine whether a compounded preparation is appropriate; the pharmacy is responsible for its preparation and labeling.
Eligibility requires a licensed clinician’s evaluation. A prescription and results are not guaranteed.
Evaluation link disconnected for website review.
Weight management
Metformin affects glucose production by the liver and the body’s response to insulin. Weight-management use is off-label: metformin is not FDA approved specifically for weight loss. This pathway provides clinical assessment of whether that use is appropriate for your circumstances, rather than automatic approval based on a purchase. The clinician reviews your medical history, kidney function, other medicines and relevant risks, and decides whether treatment and monitoring are appropriate.
Metformin commonly causes gastrointestinal effects and carries a serious warning for lactic acidosis. Kidney problems and certain other conditions or medicines can increase risk; tell the clinician about kidney or liver disease, alcohol use, planned procedures and every medicine you take. Follow the prescribed product’s instructions. Off-label use does not establish that a particular weight-loss result will occur.
Eligibility requires a licensed clinician’s evaluation. A prescription and results are not guaranteed.
Evaluation link disconnected for website review.
The Architek pathway is for adults 18 and older. Architek reports a licensed clinical network covering all 50 U.S. states and confirms GLP-1 prescribing coverage subject to applicable law. Your actual location, the treating clinician’s authorization, clinical suitability and the medicine/preparation and pharmacy’s service limits must be checked before any charge. This is self-pay care; the clinical service does not bill insurance. Under Architek Health Provider Network PC’s published eligibility policy, patients covered by Medicare, Medicaid or TRICARE are ineligible for this clinical pathway. Private insurance does not make this an insurance-billed service. Evaluation may be asynchronous or require a live visit; no prescription or result is guaranteed.
Not for emergencies. Call 911 or seek emergency care for a medical emergency.
